After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) has officially approved a COVID-19 vaccine from Novavax for adults 65 and older and for individuals ages 12 to 64 who have an underlying health condition that puts them at higher risk for serious illness from a coronavirus infection.

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and recommending vaccines.

FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.”

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

A top agency official is meeting with industry and FDA staff as he works on guidance clarifying the FDA’s expectations for vaccines.

FDA set to change requirements to get vaccines approved as RFK Jr continues to push skepticism about their use - New FDA framework on changes coronavirus vaccine approval will be released “in the coming days,